WO2006120525A2 - Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate - Google Patents

Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate Download PDF

Info

Publication number
WO2006120525A2
WO2006120525A2 PCT/IB2006/001132 IB2006001132W WO2006120525A2 WO 2006120525 A2 WO2006120525 A2 WO 2006120525A2 IB 2006001132 W IB2006001132 W IB 2006001132W WO 2006120525 A2 WO2006120525 A2 WO 2006120525A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
nelfinavir
mesylate
crystalline
compound
Prior art date
Application number
PCT/IB2006/001132
Other languages
French (fr)
Other versions
WO2006120525A3 (en
Inventor
Tarun Kant Sharma
Pintu G. Pathare
Prosenjit Bose
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN1103/DEL/2005 priority Critical
Priority to IN1103DE2005 priority
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2006120525A2 publication Critical patent/WO2006120525A2/en
Publication of WO2006120525A3 publication Critical patent/WO2006120525A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

The invention relates to a novel crystalline form of nelfinavir mesylate and processes for its preparation. More particularly, it relates to the preparation of crystalline form of nelfinavir mesylate designated as Form I. The invention also relates to pharmaceutical compositions that include the crystalline Form I of nelfinavir mesylate and use of said compositions for treatment of HTV-I infections. The invention also relates to a process for the preparation of nelfinavir or a salt thereof.

Description

PROCESSES FOR THE PREPARATION OF NELFINAVIR
Field of the Invention
The field of the invention relates to a novel crystalline form of nelfmavir mesylate and processes for its preparation. More particularly, it relates to the preparation of crystalline form of nelfmavir mesylate designated as Form I. The invention also relates to pharmaceutical compositions that include the crystalline Form I of nelfmavir mesylate and use of said compositions for treatment of HTV-I infections. The invention also relates to a process for the preparation of nelfmavir or salts thereof.
Background of the Invention
Nelfmavir is chemically, [35f-[2(25*,35*),3α)4αp,8αβ]]-iV-(l)l- dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4- (phenylthio)butyi]-3-isoquinoline carboxamide. It is commercially available in the form of its mono-methanesulfonate salt of structural Formula I.
Figure imgf000002_0001
FORMULA I
Nelfmavir belongs to the class of HIV-protease inhibitors indicated for the treatment of HIV infection when antiretro viral combination therapy is warranted. It was originally used in combination with antiretroviral nucleoside analogues for the treatment of HIV-I in adults, adolescents and children. Nelfmavir is a member of the group of drugs referred to as protease inhibitors (Pis). This class of drag combats viral replication of HIV by blocking HIV's protease protein. This protein or enzyme is used by HIV to break up large viral proteins into smaller particles from which new HIV particles can be formed. Protease inhibitors ensure that these new particles are immature and incapable of infecting new cells, thus inhibiting the HIV replication process.
Several processes have been reported for the preparation of nelfmavir for example, in International (PCT) Publication Nos. WO 95/09843; 98/09951; 98/09952; and 01/29013; and European Patent No. 983,999. All the processes provide amorphous nelfmavir mesylate.
Summary of the Invention The present inventors have found a new crystalline form of nelfmavir mesylate and have developed a process for preparation of the crystalline form. The new crystalline form of nelfmavir mesylate is designated as Form I.
In one general aspect there is provided a crystalline Form I of nelfmavir mesylate.
The Form I of nelfmavir mesylate may have the X-ray diffraction pattern of Figure 1, differential scanning calorimetry thermogram of Figure 2, and infrared spectrum of Figure 3.
In one general aspect there is provided a process for the preparation of Form I of nelfmavir mesylate. The process includes obtaining a solution of nelfmavir in one or more organic solvents; contacting the solution with methanesulphonic acid; and isolating the crystalline Form I of nelfinavir mesylate by the removal of the solvents. Removing the solvents may include, for example, one or more of filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum.
The process may include further drying the product obtained.
In another general aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of the crystalline Form I of nelfinavir mesylate; and one or more pharmaceutically acceptable carriers, excipients or diluents.
In another general aspect there is provided a method for treating HIV-I infections in a warm-blooded animal. The method includes providing a pharmaceutical composition to the warm-blooded animal, the pharmaceutical composition comprising Form I of nelfmavir mesylate.
The present inventors also have developed a one-pot reaction for the preparation of nelfmavir. The present process does not involve the isolation of any intermediate, thereby reducing the work-up time as well as the cost of production. By following the present process, the yield of the final product nelfmavir, is also considerably improved.
In one general aspect there is provided a process for the preparation of nelfmavir or a salt thereof. The process includes: a) reacting a compound of Formula II or a salt thereof,
Figure imgf000004_0001
FORMULA II wherein R1 and R2 are independently hydrogen or amino protecting group with a proviso that both R1 and R2 are not hydrogen or R1 and R2 do not combine together to form a divalent amino protecting group, with 3-t-butylcarboxamide perhydroisoquinoline of Formula III,
Figure imgf000004_0002
FORMULA III get a compound of Formula IV,
Figure imgf000005_0001
FORMULA IV wherein R1 and R2 are as described above; b) deprotecting the compound of Formula IV to get a compound of Formula V;
Figure imgf000005_0002
FORMULA V
C) condensing the compound of Formula V with a compound of Formula VI,
Figure imgf000005_0003
FORMULA VI wherein R3 represents a hydroxy protecting group, to get protected nelfϊnavir; d) deprotecting the hydroxy protecting group of the protected nelfmavir; and e) isolating the nelfmavir or a salt thereof, wherein all the above steps are carried out in- situ without isolation of any intermediate.
Embodiments of this process may include the deprotection being carried out in the presence of inorganic or organic bases. Removal of the hydroxy protecting group provides nelfmavir, which can be then converted to its salt.
The term "protecting group" in the present invention refers to those used in the art and serves the function of blocking the amino or hydroxyl groups while the reactions are carried out at other sites of the molecule. Suitable amino and hydroxy protecting groups are known to a person skilled in the art. Examples of hydroxyl and amino protecting groups include, but not limited to, lower alkylsilyl groups, lower alkoxymethyl groups, aralkyl groups, acyl groups, lower alkoxycarbonyl groups, alkenyloxycarbonyl groups and aralkyloxycarbonyl groups.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
Description of the Drawings
Figure 1 is an X-Ray Diffraction Pattern of crystalline Form I of nelfmavir mesylate. Figure 2 is a Differential Scanning Calorimetric (DSC) thermogram of crystalline Form I of nelfϊnavir mesylate. Figure 3 is a Fourier Transform Infrared (FTIR) spectrum of crystalline Form I of nelfmavir mesylate.
Detailed Description of the Invention
The inventors have developed a process for the preparation of a new crystalline form of nelfmavir mesylate. More particularly, the inventors have developed a process for the preparation of a crystalline Form I of nelfmavir mesylate. The term "Form I" of nelfinavir mesylate refers to a crystalline form of nelfinavir mesylate having X-ray diffraction pattern as depicted in Figure 1.
A first aspect of the invention provides a process for the preparation of crystalline Form I of nelfinavir mesylate wherein the process includes the steps of: a) obtaining a solution of nelfinavir in one or more organic solvents: b) contacting the solution with methanesulphonic acid; and c) isolating the crystalline Form I of nelfinavir mesylate by the removal of the solvents.
The inventors also have developed pharmaceutical compositions that contain the crystalline Form I of nelfinavir mesylate in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients.
In general, the solution of nelfinavir may be obtained by dissolving nelfinavir in a suitable solvent. Alternatively, such a solution may be obtained directly from a reaction in which nelfinavir is formed. The solvent containing nelfinavir may be heated to obtain a solution. It may be heated from about 3O0C to about reflux temperature of the solvent used, for example from about 5O0C to about 1000C. It may be heated from about 10 minutes to about 24 hours. More particularly, it maybe heated for about 1-2 hours.
The nelfinavir which is used as the starting material can be prepared according to the process of the present invention or by method disclosed in any of the known processes, for example, processes as disclosed in International (PCT) Publication Nos. WO 95/09843; 98/09951; 98/09952; and 01/29013; and European Patent No. 983,999.
The term "obtaining" includes dissolving, slurrying, stirring or a combination thereof.
The term "suitable solvents" includes any solvent or solvent mixture in which nelfinavir can be solubilized, including, for example, alkanols, ketones, nitriles, chlorinated hydrocarbons, polar aprotic solvents, esters, ethers, or mixtures thereof. The alkanol may include one or more of methanol, ethanol, n-propanol, isopropanol and butanol. The ketone may include one or more of acetone, ethyl methyl ketone, methyl isobutyl ketone, and diisobutyl ketone.
In general, the solution may be cooled to obtain Form I of nelfinavir mesylate. It may be cooled from about 5O0C to about 1O0C, for example from about 4O0C to about 2O0C. In one aspect, the solution may be seeded with crystals of Form I resulting in the precipitation of the Form I of nelfinavir mesylate and removing the solvent there from by filtration, filtration under vacuum, decantation or centrifugation.
The product obtained may be further or additionally dried to achieve the desired moisture values. For example, the product may be further or additionally dried in a tray drier, dried under vacuum and/or in a Fluid Bed Dryer.
In general, the crystalline Form I of nelfinavir mesyalte may be characterized by X-ray diffraction peaks at about 7.74, 9.54, 10.84, 11.16, 12.00, 12.40, 12.90, 13.42, 13.56, 15.40, 16.54, 17.26, 17.66, 18.14, 18.60, 19.20, 19.60, 20.08, 20.86, 21.82, 22.16, 22.96, 23.46, 23.84, 24.42, 25.04, 25.24, 25.70, 26.08, 26.24, 26.70, 27.08, 27.42, 27.98, 28.20, 28.58, 29.28, 29.40, 30.08, 30.22, 30.78, 31.82, 32.34, 32.76, 32.92, 33.44, 33.62, 34.32, 34.62, 34.72, and 36.12.
The crystalline Form I of nelfinavir mesylate may also be characterized by Differential Scanning Calorimetric (DSC) thermogram as depicted in Figure II having characteristic endothermic peak between 1180C and 1280C. The resulting crystalline Form I is pure and stable at normal and accelerated stability conditions.
The Form I of nelfinavir mesylate may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. In these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients. The crystalline Form I of nelfinavir mesylate can be administered for the treatment of
HIV- 1 infections in combination with other antiretroviral agents, in a warm-blooded animal. For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
A second aspect of the invention provides a process for the preparation of nelfinavir or a salt thereof. The process includes: a) reacting a compound of Formula II or a salt thereof,
Figure imgf000009_0001
FORMULA II wherein R1 and R2 are independently hydrogen or amino protecting group with the provisos that both R1 and R2 are not hydrogen or R1 and R2 do not combine together to form a divalent amino protecting group, with 3-t-butylcarboxamide perhydroisoquinoline of Formula III,
Figure imgf000009_0002
FORMULA III get a compound of Formula IV,
Figure imgf000010_0001
FORMULA IV wherein R1 and R2 are as described above; b) deprotecting the compound of Formula IV to get a compound of Formula V;
Figure imgf000010_0002
FORMULA V
C) condensing the compound of Formula V with a compound of Formula VI,
Figure imgf000010_0003
FORMULA VI wherein R3 represents hydroxy protecting group, to get protected nelfmavir; d) deprotecting the hydroxy protecting group of protected nelfinavir; and e) isolating the nelfinavir or a salt thereof from the reaction mixture thereof, wherein all the above steps are carried out in-situ without isolation of any intermediate.
The inventors have developed a one pot process for the preparation of nelfinavir or salts thereof by reacting a compound of Formula II or a salt thereof with 3-t- butylcarboxamide perhydroisoquinoline of Formula III to get a compound of Formula IV; deprotecting the compound of Formula IV to get a compound of Formula V; condensing the compound of Formula V with a compound, of Formula VI to get protected nelfinavir; deprotecting the hydroxy protecting group of the protected nelfinavir; and isolating the nelfinavir or a salt thereof from the reaction mixture thereof.
A solution of (2S,3R)-l,2-epoxy-3-N-(protected)-amino-4-phenylthiobutane of Formula II and 3-t-butylcarboxamide perhydroisoquinoline of Formula III is stirred in a suitable solvent, including, for example alkanols, ketones, polar aprotic solvents, chlorinated hydrocarbons, non-polar aprotic solvents, esters, ethers and mixtures thereof. It may be stirred from about 1 hour to about 24 hours at about 3O0C to about 1000C and the reaction is monitored for formation of compound of Formula IV. An aqueous solution of a suitable deprotecting agent is added after completion of the reaction to deprotect the protected-amino group in the compound of formula IV to get a compound of formula V. The resulting suspension is heated from about 3O0C to reflux temperature for about 1-30 hours. Water and a suitable organic solvent, including, for example chlorinated hydrocarbons, non-polar aprotic solvents, esters, ethers and mixtures thereof is added to the reaction mixture. The organic layer is separated and treated with a base. A solution of 3-O-protected-2-methyl benzoyl chloride (compound of formula VI) in an organic solvent, including, for example chlorinated hydrocarbons, non-polar aprotic solvents, esters or ethers is added to the reaction mixture at about 50C to about 3O0C and stirred for about 0.5-1 hour. Water is added to the reaction mixture and the organic layer is separated. The solvent may be evaporated under vacuum at about 250C to about 4O0C to obtain O-protected nelfinavir. A suitable organic solvent, including, for example alkanols, ketones, polar aprotic solvents, chlorinated hydrocarbons, non-polar aprotic solvents, esters, and ethers is added to the resulting residue and treated with a suitable deprotecting agent to deprotect the O-protected nelfinavir. The pH of the reaction mixture is adjusted to about 7-8. Water is charged and the resulting mass is heated to about 4O0C to about 7O0C, filtered, washed and dried to obtain nelfinavir free base. Nelfinavir free base may be converted to its salts. The term "deprotecting agent" in the present invention refers to those used in the art and serves the function of removing the protecting groups. Suitable deprotecting agents are known to a person skilled in the art. Examples of deprotecting agents include, but not limited to, inorganic and organic bases such as hydroxides, alkoxides, carbonates, or bicarbonates of alkali and alkaline earth metals, ammonia, triethylamine, dicyclohexylamine amine, diisopropylamine, and the like.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1: Preparation of nelfinavir free base A solution of (2S,3R)- 1 ,2-epoxy-3N-(benzyloxycarbonyl)-amino-4-phenylthiobutane (50 g) and 3-t-butylcarboxamide perhydroisoquinoline (39.9 g) in ethanol (100 ml) was stirred at 4O0C for 15 hours and the progress of the reaction was monitored (Thin Layer Chromatography/High Performance Liquid Chromatography). After the completion of reaction, a solution of sodium hydroxide (12.1 g) in water (12.1 ml) was added. The resulting suspension was heated to reflux for 20 hours. Water (250 ml) and dichloromethane (250 ml) were added and the mixture was stirred for 10 minutes and allowed to settle. The lower dichloromethane layer was collected. Triethylamine (42 ml) was added to the dichloromethane layer under stirring. This mixture was added drop wise to a solution of 3- acetoxy-2 -methyl benzoyl chloride (32.3 g) in dichloromethane (100 ml) at 5-250C in 30 minutes. The reaction mixture was stirred for 30 minutes and monitored (Thin Layer
Chromatography/High Performance Liquid Chromatography). Water (250 ml) was charged followed by stirring for 10 minutes. This mixture was allowed to settle for 5 minutes and the dichloromethane layer was collected. The solvent was evaporated at 350C under vacuum. To the resulting paste, ethanol (100 ml) and a solution of sodium hydroxide (12.1 g) in water (12.1 ml) were added and the mixture was stirred for 2 hours and the reaction monitored (Thin Layer Chromatography/High Performance Liquid Chromatography). The pH of the mixture was adjusted to 7.5 by adding a mixture of acetic acid (15 ml) in water (15 ml). Water (750 ml) was charged and the resulting white mass was heated to 6O0C and stirred for 1 hour. The white solid was filtered and slurry washed with water. The solid so obtained was dried in air at 8O0C to afford nelfϊnavir free base.
Purity = 80% by HPLC
Example 2: Preparation of crystalline Form I of nelfinavir mesylate Nelfϊnavir obtained in Example 1 was suspended in acetone (600 ml) and the suspension heated to 550C. Methane sulphonic acid (14.2 g) was added and the reaction mixture was stirred for 15 minutes at 550C. Active carbon was charged at 550C with stirring for 15 minutes followed by filtration through hyflo. The resulting clear filtrate was stirred for 2.0 hours at room temperature and heated to reflux for 1 hour. After this period, heating was stopped and the reaction mixture was allowed to attain a temperature of 4O0C, filtered and slurry washed with acetone (50 ml x 2). The solid so obtained was dried under vacuum at 8O0C for 24 hours to obtain crystalline Form I of nelfinavir mesylate. Yield = 65 g
Purity = 99.5% by HPLC While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. For example, the compounds described herein can be formulated into dosage forms that are suitable for administering to patients in need of the compound for treating a medical condition for which the compound is indicated, approved, or otherwise beneficial. Specifically, the Form I of nelfinavir can be formulated with one or more pharmaceutically acceptable excipients and/or with one or more active ingredients into a dosage form and administered to treat HIV-I infections.

Claims

We Claim: 1. Crystalline Form I of nelfϊnavir mesylate.
2. Crystalline Form I of nelfϊnavir mesylate having characteristic X-ray diffraction peaks at 2-theta values of about 7.74, 9.54, 10.84, 11.16, 12.00, 12.40, 12.90, 13.42, 13.56, 15.40, 16.54, 17.26, 17.66, 18.14, 18.60, 19.20, 19.60, 20.08, 20.86, 21.82, 22.16, 22.96, 23.46, 23.84, 24.42, 25.04, 25.24, 25.70, 26.08, 26.24, 26.70, 27.08, 27.42, 27.98, 28.20, 28.58, 29.28, 29.40, 30.08, 30.22, 30.78, 31.82, 32.34, 32.76, 32.92, 33.44, 33.62, 34.32, 34.62, 34.72, and 36.12.
3. The crystalline Form I of nelfmavir mesylate of claim 2 having differential scanning calorimetric endothermic peak at about 1180C to about 1280C.
4. A process for the preparation of crystalline Form I of nelfmavir mesylate, the process comprising: a) obtaining a solution of nelfmavir in one or more organic solvents: b) contacting the solution with methanesulphonic acid; and c) isolating the polymorphic Form I of nelfϊnavir mesylate by the removal of the solvents.
5. The process of claim 4, wherein the organic solvent comprises one or more of alkanols, ketones, nitriles, chlorinated hydrocarbons, polar aprotic solvents, esters, ethers, or mixtures thereof.
6. The process of claim 5, wherein the alkanol comprises one or more of methanol, ethanol, n-propanol, isopropanol, butanol and isobutanol.
7. The process of claim 4, wherein removing the solvent comprises one or more of filtration, filtration under vacuum, decantation, centrifugation, distillation and distillation under vacuum.
8. The process of claim 4, further comprising additional drying of the product obtained.
9. The process of claim 4, wherein the crystalline Form I of nelfinavir mesylate has the X-ray diffraction pattern of Figure 1. 11. A process for the preparation of nelfinavir or a salt thereof, the process comprising: a) reacting a compound of Formula II or a salt thereof,
Figure imgf000015_0001
FORMULA II wherein R1 and R2 are independently hydrogen or amino protecting group with a proviso that both R1 and R2 are not hydrogen or R1 and R2 do not combine together to form a divalent amino protecting group, with 3-t-butylcarboxamide perhydroisoquinoline of Formula III,
Figure imgf000015_0002
FORMULA III get a compound of Formula IV,
Figure imgf000016_0001
FORMULA IV wherein R1 and R2 are as described above; b) deprotecting the compound of Formula IV to get a compound of Formula V;
Figure imgf000016_0002
FORMULA V c) condensing the compound of Formula V with a compound of Formula VI,
Figure imgf000016_0003
FORMULA VI wherein R3 represents a hydroxy protecting group, to get protected nelfmavir; d) deprotecting the hydroxy protecting group of the protected nelfϊnavir; and e) isolating the nelfinavir or a salt thereof from the reaction mixture thereof, wherein all the above steps are carried out in-situ without isolation of any intermediate. 12. The process of claim 11, wherein the step a) is carried out in an organic solvent comprising one or more of alkanols, ketones, polar aprotic solvents, chlorinated hydrocarbons, non-polar aprotic solvents, esters and ethers. 13. The process of claim 12, wherein the the alkanol comprises one or more of methanol, ethanol, n-propanol, isopropanol, butanol and isobutanol. 14. The process of claim 11 , wherein the deprotecting agent is a base. 15. The process of claim 11, wherein the condensation reaction is carried out in the presence of a base. 16. The process of claims 14 or 15, wherein the base comprises one or more of hydroxides, alkoxides, carbonates, bicarbonates of alkali and alkaline earth metals, ammonia, triethylamine, dicyclohexylamine amine and diisopropylamine. 17. A pharmaceutical composition comprising a therapeutically effective amount of crystalline Form I of nelfinavir mesyalte, and one or more pharmaceutically acceptable carriers, excipients or diluents. 18. A method of treating HIV-I infections in a warm blooded animal, the method comprising providing a dosage form to the warm blooded animal that includes crystalline Form I of nelfinavir mesylate.
PCT/IB2006/001132 2005-05-03 2006-05-03 Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate WO2006120525A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1103/DEL/2005 2005-05-03
IN1103DE2005 2005-05-03

Publications (2)

Publication Number Publication Date
WO2006120525A2 true WO2006120525A2 (en) 2006-11-16
WO2006120525A3 WO2006120525A3 (en) 2007-05-10

Family

ID=37396928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001132 WO2006120525A2 (en) 2005-05-03 2006-05-03 Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate

Country Status (1)

Country Link
WO (1) WO2006120525A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120525A3 (en) * 2005-05-03 2007-05-10 Ranbaxy Lab Ltd Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021964A2 (en) * 2004-08-23 2006-03-02 Matrix Laboratories Ltd Novel crystalline forms of nelfinavir mesylate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120525A2 (en) * 2005-05-03 2006-11-16 Ranbaxy Laboratories Limited Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021964A2 (en) * 2004-08-23 2006-03-02 Matrix Laboratories Ltd Novel crystalline forms of nelfinavir mesylate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LONGER M: "FORMULATION DEVELOPMENT AND EVALUATION OF VIRACEPTTM (NELFINAVIR MESYLATE) TABLETS" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 13, no. 9, SUPPL, 1996, pages S-349, XP008015125 ISSN: 0724-8741 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120525A3 (en) * 2005-05-03 2007-05-10 Ranbaxy Lab Ltd Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate

Also Published As

Publication number Publication date
WO2006120525A3 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
KR20050040837A (en) α-Form or β-form crystal of acetanilide derivative
US8481730B2 (en) Method of synthesis of Bosentan, its polymorphic forms and its salts
CA3060121A1 (en) Polymorphic form of compound, preparation method and use thereof
JP5439168B2 (en) Rosuvastatin zinc salt
FI110096B (en) A process for the preparation of a therapeutically useful crystalline Tiagabine hydrochloride monohydrate
WO2017118945A1 (en) Premix of dapagliflozin and process for the preparation thereof
WO2013124385A2 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
JP3539926B2 (en) Antiviral pyrimidinedione derivatives and methods for their production
JP2004504319A (en) New method for producing 4-phenylpiperidine derivative
WO2006120525A2 (en) Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate
WO2014030173A2 (en) An improved process for the preparation of atazanavir bisulfate
CA2164296C (en) Heterocyclic chemistry
JP3718262B2 (en) Phosphinic acid derivatives, process for their preparation and use thereof
US4283422A (en) 3-Amino-4-homoisotwistane derivatives
US11111208B2 (en) Process for the preparation of safinamide mesylate intermediate
CN112940009A (en) Sulfonic acid polycyclic compound, pharmaceutical composition and application thereof
CN112028940B (en) Tenofovir phosphate crystal form and preparation and application thereof
JP2020505325A (en) [(1S) -1-[(2S, 4R, 5R) -5- (5-amino-2-oxo-thiazolo [4,5-d] pyrimidin-3-yl) -4-hydroxy-tetrahydrofuran-2- [Il] propyl] Acetate new solid
JP2019523273A (en) Verinostat polymorphic forms and process for their preparation
CN112500308A (en) Golden acylamide alcohol ester and fluorinated derivative thereof, preparation method and application
CN112624983A (en) Biphenyl diaryl pyrimidine derivative containing alkyl structure and preparation method and application thereof
CN106699812A (en) Method for preparation and purification of tenofovir prodrug
EP0971916A1 (en) N-(arginyl)benzenesulphonamide derivatives and use thereof as antithrombotic agents
WO1983004022A1 (en) New phenyloxoalkyl piperidines, methods for obtaining them and pharmaceutical compositions containing them
CZ12614U1 (en) Amlodipine maleate and pharmaceutical preparation

Legal Events

Date Code Title Description
WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 9222/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase in:

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744638

Country of ref document: EP

Kind code of ref document: A2